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Comparative Clinical Outcomes of
Paclitaxel- and Sirolimus-Eluting Stents
Results From a Large Prospective
Multicenter Registry—STENT Group
Charles A. Simonton, MD, FACC, FSCAI,* Bruce Brodie, MD,† Barrett Cheek, MD,‡
Fred Krainin, MD,§ Chris Metzger, MD, James Hermiller, MD,# Stanley Juk, MD,**
Peter Duffy, MD,†† Angela Humphrey, MS,‡‡ Marcy Nussbaum, MS,‡‡ Sherry Laurent, PHD,‡‡
for the STENT Group
Charlotte, Greensboro, High Point, and Pinehurst, North Carolina; Florence and Columbia, South Carolina;
Kingsport, Tennessee; and Indianapolis, Indiana
Objectives The purpose of this study was to compare the 9-month clinical outcomes of patients treated with paclitaxel-
eluting stents (PES) or sirolimus-eluting stents (SES) for coronary artery stenosis.
Background The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is the first multicenter registry in the
U.S. to collect long-term outcomes of drug-eluting stents from “real-world” practice.
Methods Data on all percutaneous coronary interventions in 8 U.S. hospital centers were collected in the STENT registry
between 2003 and 2005. In this prospective, nonrandomized, observational study, the choice of procedures was
at the physicians’ discretion. Patients who only received a PES (n  4,671) or SES (n  4,555) and completed
9-month follow-up (93.8% of eligible) were included for analysis. Primary end points were death, myocardial in-
farction (MI), and target vessel revascularization (TVR) at 9 months. Secondary outcomes included major ad-
verse cardiac events (MACE) (any of the 3 primary end points) and stent thrombosis.
Results At 9 months, death, MI, and TVR occurred in 2.2%, 2.0%, and 4.1%, respectively, of the PES group and 2.5%,
2.2%, and 4.3%, respectively, of the SES group (p  NS); MACE occurred in 7.5% of the PES group and 8.0% of
the SES group (p  0.37). After adjustments for group differences in baseline characteristics, TVR (hazard ratio
[HR] 0.88, 95% confidence interval [CI] 0.70 to 1.32; p  0.26) and MACE (HR 0.95, 95% CI 0.81 to 1.12; p 
0.56) were similar for PES and SES. Stent thrombosis at 9 months occurred in 0.7% of both groups.
Conclusions The results of this study show that clinical restenosis and MACE events after PES and SES procedures in “real-
world” patients are infrequent and similar at 9 months. (J Am Coll Cardiol 2007;50:1214–22) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.019S
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“ince approval of the sirolimus-eluting stent (SES)
Cypher, Cordis Corp., Miami Lakes, Florida) in April
003 and the paclitaxel-eluting stent (PES) (Taxus, Boston
rom the *Carolinas Heart Institute, Carolinas Medical Center, Charlotte, North
arolina; †LeBauer Cardiovascular Research Foundation, Greensboro, North Caro-
ina; ‡High Point Regional Health System, High Point, North Carolina; §McLeod
egional Medical Center, Florence, South Carolina; Holston Valley Medical Center,
ingsport, Tennessee; #Indiana Heart Institute, Indianapolis, Indiana; **Sisters of
harity Providence Hospitals, Columbia, South Carolina; ††Moore Regional Hos-
ital, Pinehurst, North Carolina; and the ‡‡R. Stuart Dickson Institute for Health
tudies, Carolinas Medical Center, Charlotte, North Carolina. Supported by unre-
tricted research grants from Cordis Corporation, Boston Scientific Corporation,
ossis Medical, and The Medicines Company. A complete list of the STENT registry
tudy centers appears in the Appendix.c
Manuscript received March 20, 2007; revised manuscript received May 29, 2007,
ccepted June 18, 2007.cientific Corp., Natick, Massachusetts) in March 2004,
hese stents have gained widespread acceptance by interven-
ional cardiologists for treatment of patients with obstruc-
ive coronary artery disease (CAD). Limited data are avail-
ble from multicenter studies in the U.S. comparing clinical
utcomes between these 2 stents (1). Previous comparisons
f PES and SES in randomized multicenter trials have
roduced varying results and have been performed exclu-
ively outside the U.S. (2–8).
The STENT (Strategic Transcatheter Evaluation of New
herapies) study is the first multicenter prospective registry
o collect clinical outcomes with these 2 stents from a
real-world” patient population in the U.S. The registry was
reated to evaluate coronary stents in broad clinical settings
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September 25, 2007:1214–22 Drug-Eluting Stent Outcomes in Clinical Practicefter approval by the U.S. Food and Drug Administration
FDA) in May 2003. The primary purpose of the present
tudy was to compare 9-month clinical outcomes in patients
eceiving a PES or SES to determine differences in mortality,
linically diagnosed myocardial infarction (MI), target vessel
evascularization (TVR), or stent thrombosis (ST).
ethods
tudy population. The STENT study is a multicenter
ultidevice percutaneous coronary intervention (PCI) reg-
stry that began enrollment in May 2003. For the present
tudy, all patients enrolled from May 1, 2003, through
eptember 30, 2005, were included for analysis. Centers
ere selected to represent a mix of large tertiary referral and
maller community-based interventional cardiology pro-
rams. All centers obtained institutional review board (IRB)
pproval to prospectively consent and enroll patients. Be-
ause there were no exclusion criteria, the intent was to
nroll every patient undergoing PCI. Centers were expected
o maintain a minimum prospective enrollment of 80% of all
atients undergoing PCI and a 9-month clinical follow-up
f 90%. For patients having more than 1 procedure during
he study period, the first procedure was used for 9-month
ollow-up. Patients having lesions treated only with PES or
ES were included. Lesions could be pretreated with
alloon angioplasty or other devices and could receive
ostdilatation.
nd points. The 3 primary end points were death, clini-
ally diagnosed MI, and TVR. A TVR was defined as a
epeat procedure in the target vessel (including all of its
ranches) specifically, coronary artery bypass graft (CABG),
r repeat PCI of the target vessel. The TVR was used
nstead of target lesion revascularization, because determi-
ations were visually assessed without a core angiographic
aboratory. Secondary end points consisted of major adverse
ardiac events (MACE) (a composite of death, MI, or
VR), ST, and stroke. Stent thrombosis was defined as: 1)
ngiographic evidence of thrombus within the stent or a
eduction in Thrombolysis In Myocardial Infarction grade
o 0, 1, or 2 in the previously treated target vessel in
ssociation with an acute clinical cardiac presentation of
nstable angina or MI (acute coronary syndrome); 2)
udden cardiac death; or 3) ST-segment elevation myocar-
ial infarction (STEMI) in the target vessel distribution.
dditional end points included proportional hazards-
djusted time to TVR and time to MACE events. Any
uestionable events, all TVR and ST events, and all cardiac
eaths were adjudicated by the principal investigator at each
ite.
ata collection and management. Each of the 8 partici-
ating centers (Online Appendix A) had at least 1 coordi-
ator for consenting, collecting, and entering data into a
eb-based system. Frequent conference calls and on-site
eetings were conducted to promote homogeneity of datanterpretation and data entry. Clinical and analytical integrityf the STENT registry were mon-
tored by the Executive Steering
ommittee, which included a
rincipal investigator from each
articipating institution. All data
ere reviewed by this committee
n a regular basis through elec-
ronic communication, teleconfer-
ncing, and in-person meetings.
Prospective observational meth-
dology was used with no intent to
nfluence the practices of the par-
icipating hospitals or physicians.
ll sites were trained on study
ariable definitions using Ameri-
an College of Cardiology (ACC)
efinitions (version 2.0). For vari-
bles that were not ACC defined,
definition was provided by Steering Committee consensus.
atient baseline clinical data at hospital admission and time of
rocedure were collected by staff at each institution. Intrapro-
edural data were collected and approved by the operating
nterventional cardiologist.
Reference vessel diameters, lesion lengths, and percentage
f pre- and postprocedure stenosis in the target lesions were
Figure 1 Derivation of Study Population
Derivation of study sample from percutaneous coronary interventions (PCI)
done between May 2003 and September 2005. *Includes patients treated
with bare-metal stents or any combination of drug-eluting and/or bare-metal
stents. PES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.
Abbreviations
and Acronyms
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SAT  subacute stent
thrombosis
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TVR  target vessel
revascularization
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Drug-Eluting Stent Outcomes in Clinical Practice September 25, 2007:1214–22stimated visually by the operating physician. Stent length
er lesion and total stent length per procedure (sum of the
ndividual stent lengths deployed) consisted of the actual
ackage lengths of the stents deployed. Post-discharge
linical follow-up at 9 months was conducted at each
nstitution by telephone interview. At the time of follow-up,
omplete hospital records were obtained and reviewed for
very patient reporting a cardiac event.
An independent data coordinating and statistical center
R. Stuart Dickson Institute for Health Studies, Charlotte,
orth Carolina) was responsible for the development and
aintenance of the web-based data collection tools, extrac-
ion of the data, performance of scheduled quality checks,
nd all of the analytics. The center also employs a full-time
esearch coordinator to assist sites with IRB compliance,
ata monitoring, and quality control and a full-time auditor
or site audits. Regular audits of randomly selected proce-
ures and data fields were performed against source docu-
Baseline Patient Characteristics by Procedure G
Table 1 Baseline Patient Characteristics by
S
Patient demographics
Male, n (%)
White, n (%)
Age at procedure, yrs, mean (SD)
BMI, kg/m2, mean (SD)
Clinical history, n (%)
Family history of CAD
Hypercholesterolemia
History of CHF
Diabetes
Diet/oral therapy
Insulin therapy
History of AICD
Previous PCI
Previous CABG
Previous MI
Hypertension
Cigarette smoking (ever)
Cardiac diagnosis on hospital admission, n (%)
Acute CHF
Positive stress test
Angina
Atypical chest pain
Stable angina
Unstable angina
NSTEMI
STEMI
Any MI
Cardiogenic shock
Cardiac arrest
Asymptomatic CAD
Percentages may not sum to 100% owing to rounding. Categories m
nonmissing data.
AICD  automatic implantable cardioverter-defibrillator; BMI  bod
disease; CHF  congestive heart failure; MI  myocardial infarc
percutaneous coronary intervention; PES  paclitaxel-eluting stent; SD  sta
elevation myocardial infarction.ents on 10% of the first 4,000 procedures and 5%
hereafter.
tatistical methods. Demographic characteristics, pre-
xisting risk factors, procedure-related variables, and 9-month
utcomes were summarized using mean and standard deviation
or continuous variables and frequency and percentage for
ategoric variables. Baseline demographic, clinical, and proce-
ural characteristics were compared between the 2 groups to
etermine any significant differences. Significance testing was
onducted using t tests or the Kruskal-Wallis test for contin-
ous variables and the chi-square test or Fisher exact test for
ategoric variables depending upon the distribution. A p value
f 0.05 was considered to be statistically significant. All
nalyses were performed using SAS version 9.1 (SAS Institute,
ary, North Carolina).
Unadjusted time-to-event rates in the SES and PES
roups were calculated and compared using Cox propor-
ional hazards models to estimate the hazard ratios with
(PES and SES)
edure Group (PES and SES)
 4,555) PES (n  4,671) p Value
(66.2) 3,039 (65.3) 0.36
(86.7) 4,187 (90.1) 0.01
(11.6) 63.3 (11.8) 0.01
(5.3) 29.0 (5.2) 0.43
(35.2) 1,361 (29.1) 0.01
(68.2) 3,288 (70.4) 0.02
(8.0) 342 (7.3) 0.26
(20.7) 983 (21.1) 0.75
(10.0) 447 (9.6)
(0.8) 38 (0.8) 0.72
(29.3) 1,283 (27.5) 0.05
(15.9) 735 (15.7) 0.82
(23.3) 1,050 (22.5) 0.36
(74.4) 3,441 (73.7) 0.42
(62.6) 2,787 (59.7) 0.01
(3.8) 156 (3.3) 0.26
(24.9) 1,201 (25.7) 0.36
(2.6) 165 (3.5) 0.01
(11.0) 465 (10.0)
(46.3) 2,147 (46.1)
(18.4) 931 (20.0)
(13.5) 681 (14.6)
(31.8) 1,612 (34.5) 0.01
(0.9) 22 (0.5) 0.01
(0.8) 21 (0.5) 0.06
(3.6) 152 (3.3) 0.31
sum to totals owing to missing data. Statistical comparisons are for
index; CABG  coronary artery bypass graft; CAD  coronary artery
TEMI  non–ST-segment elevation myocardial infarction; PCI roup
Proc
ES (n
3,009
3,935
62.5
29.2
1,604
3,106
363
944
456
34
1,336
725
1,061
3,390
2,849
172
1,133
120
498
2,107
838
612
1,450
43
35
166
ay not
y mass
tion; NSndard deviation; SES  sirolimus-eluting stent; STEMI  ST-segment
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September 25, 2007:1214–22 Drug-Eluting Stent Outcomes in Clinical Practice5% confidence intervals (CIs) (9). Unadjusted Kaplan-
eier curves were constructed with corresponding log rank
ests for TVR and MACE (10). Propensity scores were used
o adjust for nonrandomization of stent selection (11). A
ogistic regression model was used where the type of stent
PES or SES) was the outcome variable and baseline
haracteristics with p  0.01 from the bivariate analysis
ere the covariates. Propensity scores were generated and
ncluded as a regression (covariance) adjustment in each of
he Cox proportional hazard regression models (11). The
bility of the propensity score to effectively balance stent
roups at baseline was confirmed using separate logistic
odels with PES/SES group type as the dependent variable
nd the covariate and propensity score as the independent
ariables (Online Appendix B). Because the propensity
cores could not balance for site, it was removed from the
ropensity model and adjusted for directly in the outcome
odels. Owing to the possibility of collinearity between site
nd stent type, hazard ratios were calculated with and
ithout site in the model.
esults
uring the study period, there were 18,379 PCI procedures
erformed at the 8 institutions (Fig. 1). Of these, informed
onsent was obtained in 16,442 (89.5%). A PES or SES
nly was performed in 10,707 procedures, and, of these,
,835 patients underwent a first procedure in the registry
eceiving only a PES or SES device. A total of 9,226
Procedural Characteristics by SES and PES Gro
Table 2 Procedural Characteristics by SES a
SES (n  4
Procedure indication, n (%)
Elective 1,348 (2
Urgent 2,646 (5
Emergent 546 (1
Salvage 12 (0
PCI presentation, n (%)
Cardiogenic shock 40 (0
Cardiac arrest 11 (0
Abrupt closure 11 (0
Acute evolving MI 379 (8
Ejection fraction, mean (SD)* 51.5 (1
Hemodynamic support, n (%)
Intra-aortic balloon pump 36 (0
Cardiopulmonary support 3 (0
Degree of CAD, n (%)†
Single vessel 1,659 (3
Multivessel 2,139 (4
Medications, n (%)
Any GP IIb/IIIa 2,656 (5
Heparin, unfractionated 2,906 (6
Enoxaparin 351 (7
Bivalirudin 1,477 (3
Percentages may not sum to 100% owing to rounding. Categories m
nonmissing data. *Ejection fraction contains 18.7% SES and 15.7%
missing values.
GP  glycoprotein; other abbreviations as in Table 1.atients (93.8% of eligible) were followed up at 9 months
nd constitute the study population.
The PES stent group was significantly older, had a higher
ercentage of whites, and had a higher incidence of MI on
dmission (Table 1). The SES group had a significantly
igher incidence of cigarette use, hypercholesterolemia,
rior PCI, cardiogenic shock, cardiac arrests, and more
requent family history of CAD. All of these differences,
lthough statistically significant, were numerically small.
here were no other significant differences in risk factors,
uch as diabetes, or clinical presentation between the 2
roups.
There were few significant differences between the 2
roups at the time of the procedure (Table 2). On presen-
ation to the catheterization laboratory, the SES group had
ore urgent procedures compared with the PES group,
hich had more emergent procedures mostly because of a
lightly higher frequency of acute evolving MI (PES 9.9%
s. SES 8.3%; p  0.01). Other procedural factors that
ould impact clinical outcome, such as left ventricular
jection fraction, congestive heart failure, and degree of
AD, were not significantly different.
The PES was used significantly more frequently in
igh-risk lesions (calcification and bifurcations) and in
maller vessels (3.0 mm) (Table 3). In comparison, the
ES stent was used significantly more in saphenous vein
raphs (SVG), chronic total occlusions (CTO), and reste-
osis procedures. Other lesion factors, such as lesion length,
ES Groups
PES (n  4,671) p Value
1,534 (32.9) 0.01
2,478 (53.1)
645 (13.8)
9 (0.2)
31 (0.7) 0.28
15 (0.3) 0.56
8 (0.2) 0.50
461 (9.9) 0.01
51.5 (11.8) 0.98
32 (0.7) 0.63
7 (0.15) 0.34
1,743 (37.3) 0.18
2,389 (51.1)
2,654 (56.8) 0.15
3,331 (71.3) 0.01
361 (7.7) 0.97
1,183 (25.3) 0.01
sum to totals owing to missing data. Statistical comparisons are for
issing values. †Degree of CAD contains 16.7% SES and 11.6% PESups
nd P
,555)
9.6)
8.1)
2.0)
.3)
.9)
.2)
.2)
.3)
1.7)
.8)
.07)
6.4)
6.9)
8.3)
3.8)
.7)
2.4)
ay not
PES m
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Table 3 Comparison of Vessel and Lesion Characteristics Between SES and PES Groups
Per-Patient Analysis SES (n  4,555) PES (n  4,671) p Value
Acute procedure success, n (%)* 4,464 (98.0) 4,579 (98.0) 0.94
Number of stents, n (%)
1 3,076 (67.5) 3,126 (66.9) 0.31
2 1,136 (24.9) 1,153 (24.7)
3 343 (7.5) 392 (8.4)
Total stent length, mean (SD), mm 28.2 (17.5) 28.2 (17.4) 0.90
SVG any lesion, n (%) 293 (6.4) 211 (4.5) 0.01
CTO any lesion, n (%) 93 (2.0) 59 (1.3) 0.01
Calcium any lesion, n (%) 1,024 (22.5) 1,182 (25.3) 0.01
Bifurcation any lesion, n (%) 321 (7.1) 382 (8.2) 0.04
Ostial (Ao or Br) any lesion, n (%) 405 (8.9) 437 (9.4) 0.45
Multilesion, n (%) 1,007 (22.1) 1,097 (23.5) 0.12
Multivessel, n (%) 391 (8.6) 412 (8.8) 0.71
In-stent thrombosis any lesion, n (%) 28 (0.6) 28 (0.6) 1.00
Nonstent thrombosis any lesion, n (%) 129 (2.8) 89 (1.9) 0.01
In-stent restenosis any lesion, n (%) 228 (5.0) 186 (4.0) 0.02
Non-stent restenosis any lesion, n (%) 117 (2.6) 79 (1.7) 0.01
Lesion Characteristics (Per Lesion) SES (n  5,743) PES (n  5,980) p Value
Vessel location, n (%)
RCA 2,091 (36.4) 2,326 (38.9) 0.01
LAD 2,106 (36.7) 2,154 (36.0)
CX 1,424 (24.8) 1,340 (22.4)
Ramus 85 (1.5) 93 (1.6)
Left main 37 (0.6) 67 (1.1)
Vessel diameter, mean (SD), mm† 3.1 (0.5) 3.0 (0.4) 0.01
Vessel diameter 3 mm, n (%) 1,659 (29.9) 2,100 (36.4) 0.01
Lesion location, n (%)
Proximal 2,168 (37.8) 2,234 (37.4) 0.10
Mid 2,295 (40.4) 2,303 (38.9)
Distal 841 (14.3) 942 (15.9)
Ostial 434 (7.6) 463 (7.8)
Preprocedure TIMI grade, n (%)
0 537 (9.6) 540 (9.3) 0.38
1 151 (2.7) 170 (2.9)
2 446 (8.0) 508 (8.8)
3 4,458 (79.7) 4,584 (79.0)
Postprocedure TIMI grade 3, n (%) 5,622 (97.9) 5,839 (97.6) 0.35
Thrombus grade, n (%)
0 4,242 (76.9) 4,227 (73.2) 0.01
1 519 (9.4) 680 (11.8)
2 188 (3.4) 195 (3.4)
3 132 (2.4) 164 (2.8)
4 90 (1.6) 146 (2.5)
5 346 (6.3) 365 (6.3)
Lesion risk: ACC, n (%)‡
Low 1,151 (20.0) 1,149 (19.2) 0.01
Moderate 2,896 (50.4) 2,511 (42.0)
High 1,468 (25.6) 2,139 (35.8)
Prestenosis %, mean (SD) 86.4 (10.9) 86.7 (14.3) 0.03
Poststenosis %, mean (SD) 0.81 (4.4) 0.75 (4.9) 0.01
Lesion length, mean (SD), mm 16.3 (10.4) 16.2 (9.2) 0.21
Stent length per lesion, mean (SD), mm 22.2 (10.4) 21.9 (10.3) 0.01
Percentages may not sum to 100% owing to rounding. Categories may not sum to totals owing to missing data. Statistical comparisons are for
nonmissing data. *Acute procedure success  postprocedure stenosis reduced 50% and no death, STEMI, or urgent CABG. †Vessel diameter
contains 3.1% SES and 3.3% PES missing values. ‡Lesion risk contains 4.0% SES and 3.0% PES missing values.
ACC  American College of Cardiology; Ao  aorto-ostial; Br  branch-ostial; CTO  chronic total occlusion; CX  circumflex artery; LAD  left
anterior descending artery; RCA  right coronary artery; SVG  saphenous vein graft; TIMI  Thrombolysis In Myocardial Infarction; other
abbreviations as in Table 1.
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September 25, 2007:1214–22 Drug-Eluting Stent Outcomes in Clinical Practiceesion location, and total stent length per procedure, were
ot statistically different. At 98%, acute procedural success
as identical for both types of stents.
Nine-month unadjusted clinical outcomes (Table 4) show
o statistically significant differences between PES and SES
roups. Of note, TVR occurred in 4.1% of PES procedures
nd 4.3% of SES (p  0.76) and MACE in 7.5% of PES
nd 8.0% of SES (p  0.37). At 0.7%, ST was identical for
oth groups, with the majority (66.7% of PES and 80.7% of
ES) occurring within the first 30 days after the procedure.
troke at 9 months was infrequent for both groups (PES
.3%, SES 0.5%).
Unadjusted and adjusted hazard ratios for death, MI,
VR, and MACE are shown in Table 5. After adjustment,
sing PES as the reference group, the association between
tent type and the outcome components of MACE changed
ery little, remaining nonsignificant for death (hazard ratio
HR] 1.25, 95% confidence interval [CI] 0.91 to 1.72; p 
.18), MI (HR 0.97, 95% CI 0.71 to 1.32; p  0.85), TVR
HR 0.88, 95% CI 0.70 to 1.10; p  0.26), and MACE
HR 0.95, 95% CI 0.81 to 1.12; p  0.56). When site was
emoved from the models, the point estimates changed but
he conclusions of the tests remained the same (all were still
onsignificant). The unadjusted Kaplan-Meier curves gen-
rated for time to TVR and MACE through the first 9
onths after procedure illustrate the time-dependent dif-
erences in clinical events (Fig. 2). This analysis shows no
tatistically significant differences between the 2 stent prod-
cts for time to event for either TVR or MACE up to 9
onths.
To determine whether the similar outcomes for PES and
ES observed in the overall population were consistent
cross complex patient subgroups, unadjusted hazard ratios for
ACE were calculated for a number of subgroups (Fig. 3). A
Unadjusted Adverse Outcomes at 9 Months Com
Table 4 Unadjusted Adverse Outcomes at 9
Patient-Level Analysis SES (n 
Adverse outcomes, n (%)
Death 115 (
MI (STEMI or NSTEMI) 100 (
CABG target vessel 37 (
Re-PCI target vessel 161 (
Target vessel revascularization 194 (
MACE 363 (
CABG, nontarget vessel 22 (
Re-PCI, nontarget vessel 231 (
Stroke 22 (
In-stent thrombosis 31 (
Timing of in-stent thrombosis, n (%)
24 h 7 (
24 h to 14 days 12 (
14 to 30 days 6 (
30 days to 9 months 6 (
MACE includes death, MI, or TVR, where TVR includes CABG target ve
MACE  major adverse cardiac event; other abbreviations as in Tabimilar risk of MACE was observed across all but 3 aubgroups: men, patients with prior CABG, and patients
ith SVG lesions. However, after propensity score adjust-
ent for baseline differences in these 3 groups, only the
VG subgroup remained significant, but with wide CIs
ecause of the small sample size.
iscussion
he present study represents the largest multicenter
rospective comparison of PES and SES procedures in
atients receiving these devices in the U.S. These data
escribe clinical outcomes from a “real-world” population
f patients having more complex clinical, lesion, and
rocedural characteristics than patients included in the
andomized trials (TAXUS [Treatment of De Novo
oronary Disease Using a Single Paclitaxel-Eluting
tent]-I, -II, -IV, and -V, SIRIUS [Sirolimus-Coated
tents in De Novo Coronary Lesions], E [European]-
IRIUS, and C [Canadian]-SIRIUS) (12–18). This is
ndicated by the percentage of patients in the present
tudy with acute evolving MI (9.1%), cardiogenic shock
0.8%), multilesion procedures (22.8%), bifurcating le-
ions (7.6%), SVG lesions (5.5%), thrombotic lesions
0.6%), CTO lesions (1.7%), in-stent restenosis lesions
4.5%), and many other lesions excluded in the random-
zed trials.
Although a number of baseline characteristics differed
etween PES and SES procedures (increased age, more
TEMI, and smaller vessels in the PES group and more
VG, CTO, and in-stent restenosis lesions in the SES
roup), these differences were numerically small. Impor-
antly, most of the baseline characteristics in the 2 groups
ere similar, including the prevalence of diabetes, lesion
ength, and total length of deployed stent. Both unadjusted
ng SES and PES Groups
ths Comparing SES and PES Groups
5) PES (n  4,671) p Value
103 (2.2) 0.34
92 (2.0) 0.47
40 (0.9) 0.82
157 (3.4) 0.65
192 (4.1) 0.76
348 (7.5) 0.37
33 (0.7) 0.18
253 (5.4) 0.48
12 (0.3) 0.09
33 (0.7) 0.90
7 (21.2) 0.18
14 (42.4)
1 (3.0)
11 (33.3)
re-PCI target vessel.pari
Mon
4,55
2.5)
2.2)
0.8)
3.5)
4.3)
8.0)
0.5)
5.1)
0.5)
0.7)
22.6)
38.7)
19.4)
19.4)nd adjusted clinical outcomes at 9 months in this large
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f either of these 2 drug-eluting stent devices resulted in
lmost identical rates of adverse events. The clinical reste-
osis rate (TVR) observed here compares favorably with
hat seen in simpler lesions in previous randomized con-
rolled trials in the U.S. (14,19). The TVR rate for SES in
IRIUS at 9 months was 6.2% (19) and for PES in
AXUS-IV was 4.7% (14), compared with 4.3% for SES
nd 4.1% for PES in the present study. Although the
atients in the STENT registry are more complex than
arlier randomized trial patients, late event rates are similar
nd infrequent, most likely because of the lack of angio-
raphically driven TVR seen in randomized trials.
The results of the present study are consistent with
revious reports from outside of the U.S., such as the
ESEARCH (Rapamycin-Eluting Stent Evaluated At
otterdam Cardiology Hospital) and T (Taxus)-SEARCH
egistries from the Netherlands (20), the Milan registry
21), and the Latin American Society for Interventional
ardiology registry (22,23). In the RESEARCH and
-SEARCH registries, PES and SES from nonconcurrent
ime periods were compared and showed 1-year clinically
riven TVR rates of 5.4% and 3.7%, respectively (p  0.30)
nd overall MACE rates of 13.9% and 10.5%, respectively
p  0.74) (20). The highest TVR and MACE rates
eported come from the Milan experience in complex
esions with a median follow-up of 10.6 months, showing
VR rates of 12.5% for PES and 16.5% for SES (p  ns),
ACE rates of 18.1% for PES and 21.0% for SES (p 
s), and a propensity analysis confirming the similarity
etween devices (HR 0.87, 95% CI 0.62 to 1.25) (21). The
ES outcomes in the present study are also similar to those
nadjusted and Adjusted Hazard Ratios for Clinicalutcomes Comparing SES nd PES Groupst 9 Months
Table 5
Unadjusted and Adjusted Hazard Ratios for Clinical
Outcomes Comparing SES and PES Groups
at 9 Months
PES as Reference Group Hazard Ratio 95% CI p Value
Unadjusted
Death 1.17 (0.89–1.54) 0.27
MI (STEMI or NSTEMI) 1.12 (0.84–1.48) 0.45
TVR 1.04 (0.85–1.27) 0.72
MACE 1.07 (0.93–1.24) 0.35
Propensity adjusted with site
Death 1.25 (0.91–1.72) 0.18
MI (STEMI or NSTEMI) 0.97 (0.71–1.32) 0.85
TVR 0.88 (0.70–1.10) 0.26
MACE 0.95 (0.81–1.12) 0.56
Propensity adjusted without site
Death 1.16 (0.86–1.55) 0.34
MI (STEMI or NSTEMI) 1.07 (0.80–1.43) 0.65
TVR 0.99 (0.80–1.22) 0.92
MACE 1.03 (0.88–1.20) 0.72
atios1.00 favor PES, and ratios1.00 favor SES. The propensity score adjustment includes all
ignificant predictors except site (see Appendix B). Site was put directly into the statistical models
s a covariate along with the propensity scores.
CI  confidence interval; MACE  major adverse cardiac event; TVR  target vessel
evascularization; other abbreviations as in Table 1.eported from the e-CYPHER registry in both Europe andhe U.S. (24), with 1-year TVR and MACE rates in
-CYPHER of 3.1% and 5.8%, respectively. The PES event
ates in the present study are also similar to those reported
rom other PES registries such as MILESTONE-II
Scimed Boston Scientific Online Stents European Regis-
ry) (25,26) and ARRIVE I (TAXUS Peri-Approval Reg-
stry: A Multi-Center Safety Surveillance Program) at 1 year
27), with TVR and MACE rates in the MILESTONE-II
egistry of 5.5% and 7.5%, respectively, and for the
RRIVE I registry of 5.6% and 7.2%, respectively (27).
When comparing the results of this study with earlier
andomized trials in Europe, the similar clinical outcomes
ith PES and SES found in the present study reinforce the
esults of the REALITY (Prospective Randomized Multi-
enter Head-to-Head Comparison of the Sirolimus-
luting Stent [Cypher] and the Paclitaxel-Eluting Stent
Taxus]) study (3), but contrast with the meta-analysis
Figure 2 Freedom From TVR and MACE for PES and SES
Kaplan-Meier proportional hazards time to (A) target vessel revascularization
(TVR) and (B) major adverse cardiac events (MACE) (death, myocardial infarc-
tion, or TVR) comparing SES and PES groups (unadjusted). CI  confidence
interval; HR  hazard ratio; other abbreviations as in Figure 1.
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September 25, 2007:1214–22 Drug-Eluting Stent Outcomes in Clinical Practicetudies of PES versus SES by Kastrati et al. (7,28,29) and by
indecker et al. (5). In the REALITY study (3), which
ncluded routine angiographic follow-up, the TVR rates at
year for PES and SES were 7.9% and 8.0%, respectively
p  0.99), and the MACE rates were 11.4% vs. 10.7%,
espectively (p  0.73). The 2 published meta-analyses of
astrati et al. (7) and Windecker et al. (5) suggested
ignificantly lower clinical event rates for SES compared
ith PES patients. However, these pooled analyses are
imited, in that the majority of studies included are from one
r two center studies as opposed to multicenter studies. In
ddition, they pool trials of broader populations, such as the
EALITY (3) and SIRTAX (Sirolimus-Eluting Stent
ompared With Paclitaxel-Eluting Stent for Coronary
evascularization) (5) studies, with other narrowly selected
opulations, as in the ISAR-DIABETES (Paclitaxel-
luting Stent Versus Sirolimus-Eluting Stent for the Pre-
ention of Restenosis in Diabetic Patients With Coronary
rtery Disease) (8) and ISAR-DESIRE (Drug-Eluting
tents for In-Stent Restenosis) (28) studies. The limitation
f patient selection and effects of routine angiographic
ollow-up may reduce the ability to generalize from these
andomized trials to a broad spectrum of patients.
The results of the present study indicate that for patients
eceiving PES and SES described in this all-inclusive
egistry, the clinical outcomes at 9 months are indistin-
Figure 3 Comparative Unadjusted Rates of MACE for Overall P
Hazard ratios (HRs) of stent type for MACE in the overall patient population and sp
However, the male and prior coronary artery bypass graft (CABG) subgroups becom
lesions remain significant (HR 2.38; 95% CI 1.21 to 4.69; p  0.012). LAD  left
abbreviations as in Figures 1 and 2.uishable between the 2 stent types. Based on these results, ahe decision of which stent type to use could be made by the
hysician based on comfort with the mechanical properties
f a particular stent (e.g., deliverability, feel, balloon com-
liance) rather than expected differences in clinical out-
omes. These findings show that when the operators in this
roup of centers selected a drug-eluting stent without forced
ssignment (randomization) and based on their own judg-
ent of patient and lesion characteristics, outcomes were
imilar between PES and SES patients. The possibility that
pecific subgroups of patients may have had different out-
omes cannot be determined definitively, although it is of
nterest that similar outcomes were seen for the 2 stents
cross most of the complex subgroups.
tudy limitations. Because this registry was observational,
tudy results may be confounded by the nonrandomized
ssignment of each treatment. In addition, registry findings can
e limited by low rates of enrollment, lack of an independent
linical events committee, and under-reporting of events.
owever, this appears less likely in the present study, because
f the close and comprehensive structure of this registry
esulting from a limited number of study sites, homogeneity of
ethodology, and frequent auditing.
onclusions and Clinical Implications
his study from a large multicenter registry shows that PES
tion and Subgroups
subgroups. *These 3 subgroups show statistically significant unadjusted HRs.
significant when adjusted by propensity score. Saphenous vein graph (SVG)
ior descending artery; STEMI  ST-segment elevation myocardial infarction; otheropula
ecified
e non
anternd SES were associated with low and indistinguishable
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onths’ follow-up. The implications of these findings are
hat selection of a particular drug-eluting stent may be
etermined more by the operator’s comfort with the me-
hanical properties of the stent for a given lesion rather than
y any apparent differences in clinical outcomes.
cknowledgments
pecial appreciation is extended to the STENT registry
entral coordinator, Susan Christopher, and executive assis-
ant, Connie Poole, for their tremendous commitment to
his study. In addition, each of the individual site coordi-
ators, data coordinators, and physician operators are
hanked for their diligence and success with patient con-
ents, data collection, and follow-up.
eprint requests and correspondence: Dr. Charles A. Simonton,
anger Clinic, 1001 Blythe Boulevard, Suite 300, Charlotte, North
arolina 28203. E-mail: Charles.Simonton@carolinashealthcare.org.
EFERENCES
1. Williams DO, Abbott JD, Kip KE, DESCOVER Investigators.
Outcomes of 6906 patients undergoing percutaneous coronary inter-
vention in the era of drug-eluting stents: report of the DESCOVER
registry. Circulation 2006;114:2154–62.
2. Morice MD, Serruys PW, Colombo A, et al. Prospective randomized
multi-center, head-to-head comparison of the sirolimus-eluting stent
(Cypher) and the paclitaxel-eluting stent (Taxus): twelve-month
outcome of the REALITY trial (abstr). Am J Cardiol 2005;96 Suppl
7A:53H.
3. Morice MD, Colombo A, Meier B, et al., REALITY Trial Investi-
gators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary
artery lesions: the REALITY trial: a randomized controlled trial.
JAMA 2006;295:895–904.
4. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P.
Efficacy of drug eluting stents in patients with and without diabetes
mellitus: indirect comparison of controlled trials. Heart 2006;92:
650–7.
5. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and
paclitaxel-eluting stents for coronary revascularization. N Engl J Med
2005a;353:653–62.
6. Goy JJ, Strauffer JC, Siegenthaler M, Benoit A, Seydoux C. A
prospective randomized comparison between paclitaxel and sirolimus
stents in the real world of interventional cardiology: the TAXI trial.
J Am Coll Cardiol 2005;45:308–11.
7. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs
paclitaxel-eluting stents in patients with coronary artery disease:
meta-analysis of randomized trials. JAMA 2005;294:819–25.
8. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-
eluting stents to prevent restenosis in diabetic patients. N Engl J Med
2005;353:663–70.
9. Cox DR. Regression models and life tables. J R Stat Soc B 1972;20:
187–220.
0. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and
Hall, 1984.
1. D’Agostino RB Jr. Propensity score methods for bias reduction in the
comparison of a treatment to a nonrandomized control group. Stat
Med 1998;17:2265–81.
2. Grube E, Silber S, Hauptmann R, et al. TAXUS I: six- and
twelve-month results from a randomized, double-blind trial on a
slow-release paclitaxel-eluting stent for de novo coronary lesions.
Circulation 2003;107:38–42.
3. Colombo A, Drzewiecki J, Banning A, et al., TAXUS II Study Group.
Randomized study to assess the effectiveness of slow- and moderate- vrelease polymer-based paclitaxel-eluting stents for coronary artery
lesions. Circulation 2003;108:788–94.
4. Stone GW, Ellis SG, Cox DA, et al., TAXUS-IV Investigators. A
polymer-based, paclitaxel-eluting stent in patients with coronary artery
disease. N Engl J Med 2004;350:221–31.
5. Stone GW, Ellis SG, Cannon L, et al., TAXUS V Investigators.
Comparison of a polymer-based paclitaxel-eluting stent with a bare
metal stent in patients with complex coronary artery disease: a
randomized controlled trial. JAMA 2005;294:1215–23.
6. Moses JW, Leon MB, Popma JJ, et al., SIRIUS Investigators.
Sirolimus-eluting stents versus standard stents in patients with stenosis
in a native coronary artery. N Engl J Med 2003;349:1315–23.
7. Schofer J, Schluter M, Gershlick AH, et al., E-SIRIUS Investigators.
Sirolimus-eluting stents for treatment of patients with long athero-
sclerotic lesions in small coronary arteries: double-blind, randomised
controlled trial (E-SIRIUS). Lancet 2003;362:1093–9.
8. Schampaert E, Cohen EA, Schluter M, et al., C-SIRIUS Investiga-
tors. The Canadian study of the sirolimus-eluting stent in the
treatment of patients with long de novo lesions in small native
coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110–5.
9. Holmes DR Jr., Leon MB, Moses JW, et al. Analysis of 1-year clinical
outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting
stent versus a standard stent in patients at high risk for coronary
restenosis. Circulation 2004;109:634–40.
0. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel-
versus sirolimus-eluting stents for coronary artery disease in an
unselected population: one-year results of the Taxus-Stent Evaluated
at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll
Cardiol 2005;45:1135–41.
1. Cosgrave J, Agostoni P, Ge L, et al. Clinical outcome following
aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents
in complex coronary lesions. Am J Cardiol 2005;96:1663–68.
2. Sousa A, Abizaid AS, Hayashi EB, et al. Outcomes of percutaneous
interventions in diabetics treated with drug eluting stents or bare metal
stents: SOLACI registry results (abstr). Am J Cardiol 2005;96 Suppl
7A:31H.
3. Sousa A, Abizaid AS, Hayashi EB, et al. Different types of drug
eluting stents do not influence in the early (30 day) outcomes: insights
from SOLACI registry (abstr). Am J Cardiol 2005;96 Suppl 7A:
180H.
4. Urban P, Gershlick AH, Guagliumi G, et al., e-CYPHER Investiga-
tors. Safety of coronary sirolimus-eluting stents in daily clinical
practice: one-year follow-up of the e-CYPHER registry. Circulation
2006;21:1434–41.
5. Niemela K, Chevalier B, Stoerger H, et al. The Taxus paclitaxel-
eluting stent in high-risk patients: global usage patterns and clinical
outcomes in the “real-world” MILESTONE II registry (abstr). Am J
Cardiol 2005;96 Suppl 7A:130H.
6. Niemela K, Chevalier B, Stoerger H, Bilodeau L, Brito F, Russel ME.
Usage patterns and long-term clinical outcomes with the Taxus stent
in everyday clinical practice: the MILESTONE II global registry
(abstr). Am J Cardiol 2005;96 Suppl 7A:131H.
7. Lasala JM. Safety and long-term outcomes with the TAXUS
paclitaxel-eluting stent in everyday practice: the ARRIVE program
(abstr). Circulation 2006;118 Suppl II:II686.
8. Kastrati A, Mehilli J, Beckerath N, et al., ISAR-DESIRE Study
Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs
balloon angioplasty for prevention of recurrences in patients with
coronary in-stent restenosis: a randomized controlled trial. JAMA
2005;293:165–71.
9. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis
after coronary implantation of sirolimus- or paclitaxel-eluting stents.
Circulation 2006;113:2293–300.
APPENDIX
or a list of the STENT registry study centers and a table showing the
ropensity adjustment (p values for the statistically significant predictors
f stent type before and after propensity adjustment), please see the online
ersion of this article.
